226 related articles for article (PubMed ID: 16357841)
1. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.
Maslak P; Chanel S; Camacho LH; Soignet S; Pandolfi PP; Guernah I; Warrell R; Nimer S
Leukemia; 2006 Feb; 20(2):212-7. PubMed ID: 16357841
[TBL] [Abstract][Full Text] [Related]
2. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
[TBL] [Abstract][Full Text] [Related]
4. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.
Lübbert M; Bertz H; Wäsch R; Marks R; Rüter B; Claus R; Finke J
Bone Marrow Transplant; 2010 Apr; 45(4):627-32. PubMed ID: 19718057
[TBL] [Abstract][Full Text] [Related]
6. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
[TBL] [Abstract][Full Text] [Related]
7. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
[TBL] [Abstract][Full Text] [Related]
8. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Gore SD; Baylin S; Sugar E; Carraway H; Miller CB; Carducci M; Grever M; Galm O; Dauses T; Karp JE; Rudek MA; Zhao M; Smith BD; Manning J; Jiemjit A; Dover G; Mays A; Zwiebel J; Murgo A; Weng LJ; Herman JG
Cancer Res; 2006 Jun; 66(12):6361-9. PubMed ID: 16778214
[TBL] [Abstract][Full Text] [Related]
9. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
Klimek VM; Fircanis S; Maslak P; Guernah I; Baum M; Wu N; Panageas K; Wright JJ; Pandolfi PP; Nimer SD
Clin Cancer Res; 2008 Feb; 14(3):826-32. PubMed ID: 18245545
[TBL] [Abstract][Full Text] [Related]
10. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
11. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
12. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
[TBL] [Abstract][Full Text] [Related]
13. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
[TBL] [Abstract][Full Text] [Related]
14. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
[TBL] [Abstract][Full Text] [Related]
15. Targeting epigenetic changes in acute myeloid leukemia.
Blum W; Marcucci G
Clin Adv Hematol Oncol; 2005 Nov; 3(11):855-65, 882. PubMed ID: 16491631
[TBL] [Abstract][Full Text] [Related]
16. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
17. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Gore SD; Weng LJ; Figg WD; Zhai S; Donehower RC; Dover G; Grever MR; Griffin C; Grochow LB; Hawkins A; Burks K; Zabelena Y; Miller CB
Clin Cancer Res; 2002 Apr; 8(4):963-70. PubMed ID: 11948101
[TBL] [Abstract][Full Text] [Related]
18. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]